A LIGHTning Strike to the Metastatic Niche

Martinez-Usatorre, Amaia; Palma, Michele De

doi:10.1016/j.celrep.2020.01.027

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that the lung pre-metastatic niche vasculature can be normalized to suppress cancer seeding. Whether these early vascular changes can also be reversed at other common metastatic sites such as liver and brain needs to be determined [49].…”

Section: Vessel Targeting and Remodeling In The Pre-metastatic Nichementioning

confidence: 99%

Modulation of the Vascular-Immune Environment in Metastatic Cancer

Ganss

2021

Cancers

View full text Add to dashboard Cite

Advanced metastatic cancer is rarely curable. While immunotherapy has changed the oncological landscape profoundly, cure in metastatic disease remains the exception. Tumor blood vessels are crucial regulators of tumor perfusion, immune cell influx and metastatic dissemination. Indeed, vascular hyperpermeability is a key feature of primary tumors, the pre-metastatic niche in host tissue and overt metastases at secondary sites. Combining anti-angiogenesis and immune therapies may therefore unlock synergistic effects by inducing a stabilized vascular network permissive for effector T cell trafficking and function. However, anti-angiogenesis therapies, as currently applied, are hampered by intrinsic or adaptive resistance mechanisms at primary and distant tumor sites. In particular, heterogeneous vascular and immune environments which can arise in metastatic lesions of the same individual pose significant challenges for currently approved drugs. Thus, more consideration needs to be given to tailoring new combinations of vascular and immunotherapies, including dosage and timing regimens to specific disease microenvironments.

show abstract

Section: Vessel Targeting and Remodeling In The Pre-metastatic Nichementioning

confidence: 99%

Modulation of the Vascular-Immune Environment in Metastatic Cancer

Ganss

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The prepared soil for the “seeding” of CTCs, termed as a “metastatic niche (MN),” helps CTCs colonize and proliferate with the engagement of inflammatory cells, chemokines, and cytokines ( 4 ). Therefore, apart from CTCs, the MNs, where the seeding and colonization process of CTCs happen, would be the other desirable target for the management of early cancer metastasis ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches

Xia

Zhu

et al. 2022

Sci. Adv.

View full text Add to dashboard Cite

Limited circulating tumor cells (CTCs) capturing efficiency and lack of regulation capability on CTC-supportive metastatic niches (MNs) are two main obstacles hampering the clinical translation of conventional liposomes for the treatment of metastatic breast cancers. Traditional delivery strategies, such as ligand modification and immune modulator co-encapsulation for nanocarriers, are inefficient and laborious. Here, a multifunctional Rg3 liposome loading with docetaxel (Rg3-Lp/DTX) was developed, in which Rg3 was proved to intersperse in the phospholipid bilayer and exposed its glycosyl on the liposome surface. Therefore, it exhibited much higher CTC-capturing efficiency via interaction with glucose transporter 1 (Glut1) overexpressed on CTCs. After reaching the lungs with CTCs, Rg3 inhibited the formation of MNs by reversing the immunosuppressive microenvironment. Together, Rg3-Lp/DTX exhibited excellent metastasis inhibition capacity by CTC (“seeds”) neutralization and MN (“soil”) inhibition. The strategy has great clinical translation prospects for antimetastasis treatment with enhanced therapeutic efficacy and simple preparation process.

show abstract